EM SAQs · Lower gastrointestinal bleed
Massive lower GI bleed — resuscitation, Oakland and CTA-first pathway
ACEM-style SAQ on unstable LGIB: restrictive transfusion, CTA-first, apixaban reversal, embolisation pathway, and exclusion of brisk UGIB.
On this page
Study tools
Target exams
Model answer
Reveal model answerShowHide
Resuscitation. ABCDE. Two large-bore cannulae (14–16 G). Crossmatch 4 units / activate major haemorrhage if torrential. Balanced crystalloid boluses titrated to perfusion. Restrictive transfusion to Hb 70 g/L (80 g/L if ischaemic heart disease) — over-transfusion promotes rebleeding.[1] Urinary catheter; serial lactate and Hb. Do not give PPI, terlipressin, octreotide or routine antibiotics (upper-GI drugs). Do not give routine TXA (HALT-IT no mortality benefit).[6]
Exclude brisk UGIB. Haematochezia with shock is upper source until proven otherwise. NG aspirate if doubt; raised urea:creatinine supports digested blood; early OGD if upper pathway suspected.[1]
Anticoagulation. Life-threatening apixaban bleed → andexanet if available, else PCC 25–50 units/kg. Hold further DOAC; plan early resumption after haemostasis.[1]
Imaging. Unstable ongoing LGIB → CT angiography first, not colonoscopy (unprepped bowel + instability). CTA detects extravasation ~0.3–0.5 mL/min and triages to IR.[1] Oakland scoring is for stable patients only — not this man.
Definitive haemostasis. Positive CTA → superselective mesenteric embolisation. If embolisation fails/recurs → surgery (segmental colectomy). If stabilises → colonoscopy within 24 h after prep for endoscopic therapy (epinephrine 1:10,000 + clip/APC). HDU/ICU disposition.[1]
References3ShowHide
- [1]Sengupta N, et al. Management of Patients With Acute Lower Gastrointestinal Bleeding: An Updated ACG Guideline American Journal of Gastroenterology, 2023.PMID 36735555
- [4]Oakland K, et al. External Validation of the Oakland Score to Assess Safe Hospital Discharge Among Adult Patients With Acute Lower Gastrointestinal Bleeding in the US JAMA Netw Open, 2020.PMID 32633766
- [6]HALT-IT Trial Collaborators Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial Lancet, 2020.PMID 32563378